Pharma and Healthcare Sectors Expect Robust Growth Driven by Domestic Market and Strategic Launches

The pharmaceutical industry is poised for an 8.5% revenue growth, spurred by domestic formulations and niche US market launches. The Indian market shows a strong recovery, with key players reporting notable sales figures. Meanwhile, the healthcare sector anticipates a 9.4% growth, led by increased occupancy rates and profitability.

The pharmaceutical industry is predicted to experience significant growth, with revenue projected to increase by 8.5% year-on-year, according to a recent report by Axis Securities. This growth is primarily driven by domestic formulations and strategic product launches in the US market.

EBITDA is set to rise by 10.5% YoY, while Profit After Tax (PAT) is expected to grow by 14% YoY. The Indian market is making a robust comeback, bolstered by strong performances in chronic and acute therapies. Notably, companies like Dr. Reddy's, Cipla, and Aurobindo are forecasting substantial gRevlimid sales for the quarter.

Moreover, an improvement in margins by 40 basis points is anticipated, thanks to favorable domestic conditions, stable freight costs, and consistent API prices. The healthcare sector is also expected to see a 9.4% revenue growth, driven by improved occupancy rates, although challenges persist for certain players like Medanta due to facility-specific slowdowns.

(With inputs from agencies.)